Ivosidenib
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Ivosidenib: Exploring a Potential New Role in Bulbar Polio
One-Sentence Summary
Ivosidenib (DrugBank ID DB14568) has no original indication or mechanism-of-action data on file in this evidence pack, and it is not currently marketed in Denmark. The TxGNN model predicts a possible association with Bulbar Polio (score 99.31%), but this prediction is currently supported by no clinical trials and no published literature.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no data on file) |
| Predicted New Indication | Bulbar Polio |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L5 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for ivosidenib in this evidence pack, and no original approved indication is recorded either. As a result, the pharmacological rationale linking ivosidenib to the predicted indication (bulbar polio) cannot be assessed from the data currently on file.
Without an established original indication or MOA to compare against, this prediction should be treated purely as a model-generated hypothesis (TxGNN score only) rather than a mechanistically grounded signal. Independent verification of ivosidenib’s pharmacology and its plausibility for a viral/neurological condition such as bulbar polio is needed before this candidate can be evaluated further.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Denmark Market Information
Ivosidenib has no marketing authorisation on file in Denmark (0 licenses recorded; market status: not marketed).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Note: A blocking data gap has been identified — TFDA/product label warnings and contraindications are not yet available, which prevents a preliminary safety (S1) assessment.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has no supporting clinical trials or literature (Evidence Level L5 — model prediction only), no documented original indication or mechanism of action, and the drug is not currently marketed in Denmark. A blocking data gap on safety labeling further prevents any preliminary risk assessment.
To proceed, the following is needed:
- Original indication and confirmed mechanism of action (MOA) for ivosidenib
- Official product label / SmPC data (warnings, contraindications) to resolve the blocking data gap
- Drug-drug interaction (DDI) data (current query returned no results)
- Clinical trial or literature evidence specifically evaluating ivosidenib in bulbar polio, given the current complete absence of supporting studies
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.